Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.
Sponsor: Mater Misericordiae Limited
Listed as NCT05734040, this PHASE2 trial focuses on Influenza and remains completed. Sponsored by Mater Misericordiae Limited, it has been updated 10 times since 2023, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mater Misericordiae Limited
- Novotech (Australia) Pty Limited
- Osivax
For direct contact, visit the study record on ClinicalTrials.gov .